Medscape

FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds

A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...
The American Journal of Managed Care

New LAMA/LABA FDC Inhaler May Be Better Option for COPD Patients

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
Nature

The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis

Inhaled corticosteroid/long-acting β 2-agonist (ICS/LABA) fixed-dose combinations are recommended regular maintenance options for asthma. ICS/LABAs containing ...
Healio

LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...